Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
FOLFIRINOX regimen was recently presented at an international oncology meeting and represents
a new standard regimen in the treatment of metastatic pancreatic cancer. FOLFIRINOX is one of
the high response rate treatment regimen , the investigators considered as a promising
treatment as neoadjuvant chemotherapy . On the other hand , incidences of grade 3 or 4
neutropenia , febrile neutropenia and diarrhea were significantly higher in the FOLFIRINOX
group compared with gemcitabine group. Therefore, it was decided to consider the balance of
safety and efficacy as a preoperative chemotherapy, the investigators use the FIRINOX regimen
by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from
FOLFIRINOX regimen